PDCD1 and congenital rubella syndrome: Furthermore, anti-CD19 CAR-PD-1-CD28 T cells demonstrated a manageable safety profile with patients developing grade 1–2 CRS symptoms after infusion which resolved fully by supportive treatment or administration of tocilizumab and glucocorticoids [39, 41].